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So far, 168 patients with non-small cell lung cancer (NSCLC) or
prostate cancer have been treated with L-BLP25 vaccine in phase I
or II clinical trials. A randomized phase IIb study was performed
that compared the safety and efficacy of L-BLP25 in patients with
stage IIIB or IV NSCLC against best supportive care (BSC). Data
from this study revealed an overall median survival of 17.4
months for patients on the vaccine arm versus 13 months for
the patients in the BSC arm. Two-year survival was 43% for the
L-BLP25 vaccine arm versus 29% for the BSC arm. The median sur-
vival for patients with locoregional Stage IIIB disease (without
pleural effusion) was 30.6 months in the L-BLP25 arm and 13.3
months for patients in the control arm. Two-year survival was
60% for the L-BLP25 vaccine arm versus 37% for the BSC arm.
Safety data from the phase IIb study showed an incidence of
adverse events similar to those previously reported in L-BLP25
clinical trials, i.e. mild to moderate flu-like symptoms and injec-
tion site reactions. Although the differences in survival were sta-
tistically not significant, these results suggest a survival
advantage in locoregional stage IIIB patients treated with L-
BLP25 vaccine. A phase III trial in unresectable stage III NSCLC
patients will be launched in 2006.
doi:10.1016/j.ejcsup.2006.04.027
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Prognosis of most disseminated solid tumors remains gloomy
as neither chemotherapeutic nor unspecific immune modula-
tory approaches were able to improve the overall survival of
these patients. Hence, specific immunotherapy has received
increasing attention. Disappointing clinical results, however,
indicate that the choice of suitable antigens is of special impor-
tance. To this end, the inhibitor of apoptosis protein survivin,
which is over-expressed in several tumours but is largely unde-
tectable in adult tissues, appears to be a promising target for
vaccination purposes, since downregulation or loss of expres-
sion is associated with impaired tumour progression. Conse-
quently, heavily pretreated patients suffering from advanced,
therapy-refractory melanoma, pancreatic, cervical or colorectal
cancer were vaccinated with affinity-improved HLA-A1, A2 or
B35-restricted survivin-derived peptide epitope together with
Monatamide ISA-51 in a compassionate use setting. Preliminary
results from an interim analysis of this ongoing clinical trial
demonstrated that patients mounted strong survivin specific T
cell responses as measured by ELISPOT assay and tetramer-
staining. Furthermore, in situ peptide/HLA-A2 multimer staining
confirmed that these survivin reactive cells infiltrated both vis-
ceral and soft tissue metastases. Most importantly, clinical
activity was suggested by both disease stabilisation as well as
objective responses.
doi:10.1016/j.ejcsup.2006.04.028
S28. THE ROLE OF EGFR FAMILY IN PRENEOPLASIA AND LUNG
CANCER; PERSPECTIVES FOR TARGETED THERAPIES AND
SELECTION OF PATIENTS
Fred R. Hirsch. University of Colorado Cancer Center, United States.
The Erb-B family of receptors seems to play an important role in
the lung carcinogenesis. Several studies have demonstrated over
expression of epidermal growth factor receptor (EGFR) in bron-
chial dysplasias.1 We have studied 268 bronchial biopsies from
high-risk individuals participating in a high-risk sputum cohort
(>30 pack-years of smoking history and COPD defined as
FEV1 < 70% of expected), and EGFR protein was strongly
expressed in about 60% of patients with normal bronchial histol-
ogies, but increased with increased level of dysplasia. Also HER2
was highly expressed in both normal bronchial epithelium as well
as in preneoplasias.2
The expression of EGFR/HER2 in malignant lung tumors was
studied in several studies. Squamous cell carcinomas has most
often high expression of EGFR, but less HER2, while adenocarci-
nomas has more often high expression of HER2 and less EGFR.
Of interest is that bronchioloalveolar carcinomas has high
expression of both EGFR and HER2, which can contribute to
explain why this subtype seems to be more sensitive to EGFR
inhibitors than the other non-small cell subtypes.3
The prognostic role of EGFR and HER2 has been addressed.4,5 In
our study 183 patients with resected NSCLC were studied, and no
significant prognostic association was demonstrated in this
study. However, other studies have reported that EGFR overex-
pression is associated with poorer prognosis.5 In the UCCC study
also the EGFR gene copy number was studied by FISH, and a ten-
dency to a shorter survival was seen for increased gene copy
number.4
The predictive role of EGFR and HER2 for sensitivity to EGFR
TKIs has been studied at UCCC in two separate cohorts of NSCLC
patients. In an Italian cohort of 108 NSCLC patients we found that
EGFR protein expression, increased gene copy number detected
by FISH and EGFR gene mutations were all associated to treat-
ment outcome after EGFR TKI therapy.6 Patients with high EGFR
gene copy number (high polysomy/amplification) had a high
objective response rate (36%), disease control rate (67%) and med-
ian survival of 19 months, which was significantly better than the
patients with no or low gene gain. The same was found in another
study cohort (SWOG 0126) for patients with BAC subtypes.7 The
association between increased EGFR gene copy number and sur-
vival has been demonstrated in two randomized placebo con-
trolled studies, one with erlotinib with hazard ratio (HR) = 0.44
in the FISH positive group and in the ISEL study with gefitinib
(HR = 0.61), while no differences was seen in the FISH negative
groups.8,9
In order to identify a panel of markers, which can predict sen-
sitivity to EGFR TKIs we studied the predictive value of combined
markers. While a combination of positive IHC and positive FISH
were associated with very high response rates (41%) and pro-
longed survival (median 21 months), negative IHC and FISH
assessment was associated with no response and very short sur-
vival (median 6months) indicating no clinical benefit in this group
of patients.10 We have also performed in vitro NSCLC cell line
studies with EGFR TKIs and characterized sensitive and resistant
cell lines by Affymetrix gene chips. We have identified several
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important genes, among them E-cadherin, playing an important
role for sensitivity of EGFR TKIs.11
We conclude that while both increased EGFR gene copy num-
ber, EGFR gene mutations and over expression of EGFR protein all
associate with high response rates in NSCLC patients after EGFR
TKI therapy, only increased EGFR gene copy number by FISH
and EGFR protein expression seems to be independent predictive
factors for sensitivity to EGFR inhibitors. Patients without
increased EGFR gene copy number and lack of EGFR protein over
expression do most likely not have any clinical benefit from these
treatments.
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Two years have elapsed since mutations of the tyrosine kinase
domain of the EGFR were discovered in patients with NSCLC,
who had dramatic clinical responses to treatment with gefiti-
nib.1–3 Additional laboratory studies have provided further
insights into the biological impact of EGFR mutations and several
clinical observations have in retrospect confirmed the association
between mutations and response to the TKIs gefinitib and erloti-
nib.4 At the same time there is the suggestion that K-ras muta-
tions predict unresponsiveness to these TKIs and the fact that
K-ras mutations and EGFR mutations seem to be mutually exclu-
sive fits well in this concept.5 To validate the use of mutation sta-
tus for therapeutic decisions, we have conducted a study in which
the mutation status was determined prospectively, i.e. before the
start of treatment with TKIs.
Between June 2004 and December 2005 patients with locally
advanced or metastatic NSCLC were asked for their consent to
analyze diagnostic specimens for EGFR mutations, if they had
two out of three of the following characteristics: female gender,
non-smoking status and the diagnosis of BAC or adenocarcinoma.
Patients with a mutation in the EGFR TK domain were offered
treatment with erlotinib or gefitinib within the framework of
the compassionate use programs for these agents.
Baseline assessment included medical history (including prior
anticancer therapy), smoking history, physical examination and
vital signs, PS, complete blood cell count and blood biochemistry,
chest X-ray and tumor assessment (X-rays or computed tomogra-
phy scans). At follow-up (every 4–6 weeks), interval history, chest
X-ray, tumor assessment, complete blood count and biochemistry
were collected. Response was determined using the RECIST criteria.
We determined EGFR and K-Ras mutations by isolating DNA
from formalin-fixed paraffin embedded tumor biopsies. For EGFR
mutation analysis, exons 18–21 were PCR amplified using exon
specific primers. Since the samples were often small (biopsies)
and formalin fixed, primers were designed located in the flanking
introns, such that the size of the PCR fragments was reduced
compared to most published primers. K-ras mutation analysis
of codon 12 was performed as above.
Forty-one patients were selected for the assessment of muta-
tion status. Thirteen (out of 41 = 32%) biopsies were found to con-
tain an EGFR mutation. None of them had a K-ras mutation. The
median age of the mutation positive patients was 55, three of
them were ex-smokers and 10 were never smokers. Six of them
were male. All but four patients were chemonaive. Nine out of
the thirteen patients with mutations in the EGFR gene had an
in-frame deletion. In seven cases this was a 15 bp deletion in exon
19. The remaining four patients had a point mutation, in three
cases located in exon 21 and in one case there were 2 point muta-
tions in exon 18.
All patients with an exon 19 deletion had a swift response on
erlotinib or gefitinib. So did three out of four patients presenting
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